Curie.Bio
Crystal Shih Byers is an accomplished professional in the field of gene therapy and adeno-associated virus (AAV) research, currently serving as Senior Director at Curie.Bio since June 2024. Prior experience includes roles as Sr Director of Delivery at Moment Bio, where strategic gene delivery approaches were established, and as Director of AAV Therapeutics at Ascidian Therapeutics, where internal capabilities for AAV production were developed. Crystal's tenure at Novartis Institutes for BioMedical Research included founding the AAV core in Cambridge and leading significant therapeutic discovery programs, culminating in the receipt of the NIBR Biologics Science Prize in 2017. Educationally, Crystal holds a Ph.D. in Chemistry from Caltech and a B.S. in Chemistry from the Massachusetts Institute of Technology.
This person is not in any teams
Curie.Bio
2 followers
Curie.Bio is a founder-focused seed-stage venture firm combined with an industry-grade therapeutics accelerator focused on one thing: helping entrepreneurial founders launch viable therapeutics companies. Curie.Bio does this by giving founders access to a team of the world’s best drug hunters and drug makers, seed capital, and best-of-breed services - everything a founder needs to get from concept to a compelling quality dataset that enables an awesome Series A financing. In a nutshell, we want founders in control of their own company and focused on their area of expertise and creativity, while we help make the rest happen smoothly.